News Beckley psychedelic hits the target, unlocking atai merger The proposed merger between Beckley Psytech and atai can go ahead as a psychedelic for depression hits all its endpoints in a phase 2b trial.
News Consolidation in psychedelics as atai pairs with Beckley Beckley Psytech has agreed to merge with atai Life Sciences in a deal that would bring together two psychedelic medicine pioneers.
News atai invests $50m in Beckley Psytech Beckley Psytech has announced that it has received substantial strategic investment from Germany-based atai Life Sciences, totalling $50 million, to accelerate the clinica